27286118|t|The relationship between histological prostatitis and lower urinary tract symptoms and sexual function
27286118|a|This prospective analysis assessed the effect of histological prostatitis on lower urinary tract functions and sexual function. The patients were separated into two groups as histologically observed prostatitis (Group A) and no prostatitis (Group B) according to the biopsy outcomes. International prostate symptom score, international index of erectile function-5 scores, maximal and average flow rate, and residual urine volumes were compared statistically between groups. There was no significant difference (P>0.05) in baseline age (t=0.64), body mass index value (t=0.51), prostate volume (t=0.87), prostate-specific antigen levels (t=0.43), maximal (t=0.84) and average flow rate (t=0.59), and post-void residual urine volume (t=0.71). Mean international prostate symptom score in patients with prostatitis was numerically but not significantly higher than that in those without prostatitis (t=0.794, P=0.066). Mean international index of erectile function-5 score in the prostatitis group was significantly lower than that in those without prostatitis (t=1.854, P=0.013). Histological prostatitis notably affected sexual function of patients and may serve as a major risk factor for sexual dysfunction while having little effect on lower urinary tract symptoms.
27286118	4	16	relationship	T080	C0439849
27286118	25	37	histological	T169	C0205462
27286118	38	49	prostatitis	T047	C0033581
27286118	54	82	lower urinary tract symptoms	T184	C0574785
27286118	87	102	sexual function	T040	C0278092
27286118	108	128	prospective analysis	T062	C0033522
27286118	129	137	assessed	T052	C1516048
27286118	142	148	effect	T080	C1280500
27286118	152	164	histological	T169	C0205462
27286118	165	176	prostatitis	T047	C0033581
27286118	180	199	lower urinary tract	T022	C0729866
27286118	200	209	functions	T169	C0542341
27286118	214	229	sexual function	T040	C0278092
27286118	235	243	patients	T101	C0030705
27286118	249	258	separated	T080	C0443299
27286118	268	274	groups	T078	C0441833
27286118	278	292	histologically	T169	C0205462
27286118	293	301	observed	T169	C1441672
27286118	302	313	prostatitis	T047	C0033581
27286118	315	322	Group A	T078	C0441833
27286118	328	342	no prostatitis	T033	C0243095
27286118	344	351	Group B	T078	C0441833
27286118	370	376	biopsy	T060	C0005558
27286118	377	385	outcomes	T169	C1274040
27286118	387	423	International prostate symptom score	T170	C1998280
27286118	425	474	international index of erectile function-5 scores	T201	C2959364
27286118	476	483	maximal	T033	C0429784
27286118	488	505	average flow rate	T033	C0429785
27286118	511	533	residual urine volumes	T033	C0429774
27286118	539	547	compared	T052	C1707455
27286118	570	576	groups	T078	C0441833
27286118	591	602	significant	T081	C0237881
27286118	603	613	difference	T080	C1705242
27286118	626	634	baseline	T081	C1442488
27286118	635	638	age	T032	C0001779
27286118	649	670	body mass index value	T201	C1305855
27286118	681	696	prostate volume	T081	C1441416
27286118	707	739	prostate-specific antigen levels	T059	C0201544
27286118	750	757	maximal	T033	C0429784
27286118	771	788	average flow rate	T033	C0429785
27286118	803	812	post-void	T079	C1439885
27286118	813	834	residual urine volume	T033	C0429774
27286118	845	849	Mean	T081	C0444504
27286118	850	886	international prostate symptom score	T170	C1998280
27286118	890	898	patients	T101	C0030705
27286118	904	915	prostatitis	T047	C0033581
27286118	920	931	numerically	T081	C0243174
27286118	940	960	significantly higher	T081	C4055637
27286118	980	987	without	T080	C0332288
27286118	988	999	prostatitis	T047	C0033581
27286118	1020	1024	Mean	T081	C0444504
27286118	1025	1073	international index of erectile function-5 score	T201	C2959364
27286118	1081	1092	prostatitis	T047	C0033581
27286118	1093	1098	group	T078	C0441833
27286118	1103	1122	significantly lower	T081	C4055638
27286118	1142	1149	without	T080	C0332288
27286118	1150	1161	prostatitis	T047	C0033581
27286118	1182	1194	Histological	T169	C0205462
27286118	1195	1206	prostatitis	T047	C0033581
27286118	1215	1223	affected	T169	C0392760
27286118	1224	1239	sexual function	T040	C0278092
27286118	1243	1251	patients	T101	C0030705
27286118	1271	1276	major	T080	C0205164
27286118	1277	1288	risk factor	T033	C0035648
27286118	1293	1311	sexual dysfunction	T047	C0549622
27286118	1332	1338	effect	T080	C1280500
27286118	1342	1370	lower urinary tract symptoms	T184	C0574785